spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  spinal muscular atrophy 

 HSMN NewsFeed - 26 Sep 2024
FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 12 Jun 2024
REGENXBIO Announces Leadership Transition
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 May 2024
Alcyone Therapeutics Announces Appointment of Dr. Norbert Riedel as Chairman of the Board and Dr. Kathrin Meyer as Chief Scientific Officer and Head of Research & Development
Biopharmaceuticals Drug Delivery Neurology Personnel
 HSMN NewsFeed - 25 Feb 2022
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Nov 2021
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 23 Jun 2021
Evrysdi(TM) Approved in Japan for the Treatment of Spinal Muscular Atrophy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Apr 2021
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Mar 2021
PTC Therapeutics Announces the European Approval of Evrysdi(TM) for the Treatment of Spinal Muscular Atrophy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 Aug 2020
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 9 Jan 2020
Ionis Appoints Onaiza Cadoret-Manier As Chief Corporate Development and Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 30 Oct 2019
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 15 Oct 2019
World Renowned Experts Appointed to Skyhawk Therapeutics Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2019
Skyhawk Therapeutics Announces Expansion of Collaboration Agreement with Biogen
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Mar 2019
Novartis receives FDA approval for Mayzent(R) (siponimod), the first oral drug to treat secondary progressive MS with active disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 11 Mar 2019
Alcyone Lifesciences Receives Breakthrough Device Designation from U.S. FDA for the ThecaFlex DRx(TM) System
Devices Neurology Oncology Drug Delivery FDA
 HSMN NewsFeed - 30 Jan 2019
ArcherDX Acquires Baby Genes, a Genetics-Based Personalized Medicine Company
Diagnostics Mergers & Acquisitions
 HSMN NewsFeed - 5 Jul 2018
New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI(TM) (inotersen) for the Treatment of Hereditary ATTR Amyloidosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Jun 2018
Ionis Pharmaceuticals Appoints Damien McDevitt as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Mar 2018
Ionis and Akcea Partner to Commercialize Inotersen for hATTR
Biopharmaceuticals Licensing
 HSMN NewsFeed - 23 Jan 2018
Skyhawk Therapeutics Launches With $8 Million in Seed Financing to Advance Its Novel Platform and Portfolio of Small Molecules That Correct RNA Expression
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 9 Nov 2017
Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Nov 2017
Ionis Announces Management Transitions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jul 2017
Quest Diagnostics Launches QHerit(TM), a Pan-Ethnic Genetic Screening Panel Aligned with New Medical Guidelines
Diagnostics Product Launch
 HSMN NewsFeed - 1 Jun 2017
SPINRAZA(R) (nusinersen) Approved in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 May 2017
Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 29 Mar 2017
FDA Approves Genentech’s OCREVUS(TM) (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 6 Mar 2017
BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 26 Dec 2016
SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Dec 2016
Positive Phase III Results of Genentech’s Investigational Medicine OCREVUS(TM) (Ocrelizumab) Published in New England Journal of Medicine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Dec 2016
Biogen Names Michel Vounatsos Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jun 2016
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 17 Feb 2016
FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 19 Jan 2016
Akcea Therapeutics Appoints Louis St. L. O'Dea as Chief Medical Officer
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 5 Jan 2016
Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 23 Jul 2015
RaNA Therapeutics Secures $55 Million in Oversubscribed Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Jun 2015
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif(R)) in Two Phase III Studies in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Jan 2015
Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Sep 2013
Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 29 Jun 2012
Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Myotonic Dystrophy
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2012
Paratek Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Sep 2011
iPierian Appoints Nancy Stagliano as CEO; Peter Van Vlasselaer, Interim CEO, Becomes Executive Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jun 2011
Repligen Receives U.S. Fast Track Designation and European Orphan Medicinal Product Recommendation for RG3039 for Spinal Muscular Atrophy
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2011
AVI BioPharma Names Ed Kaye, M.D., Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Oct 2010
AVI BioPharma Announces Key Leadership Appointments to Advance Capabilities in Drug Discovery, Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2010
iPierian Announces Second Close of $28 Million Series B Financing
Biopharmaceuticals Regenerative Medicine Venture Capital
 HSMN NewsFeed - 8 Jul 2010
iPierian Closes $22 Million Series B Financing Led By Google Ventures
Biopharmaceuticals Regenerative Medicine Venture Capital
 HSMN NewsFeed - 23 Feb 2010
iPierian Appoints Dr. Michael Venuti as President and Chief Scientific Officer
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 19 Jan 2010
PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
Biopharmaceuticals
 HSMN NewsFeed - 21 Dec 2009
California Stem Cell, Inc Closes Series B Financing Round
Regenerative Medicine Venture Capital
 HSMN NewsFeed - 8 Dec 2009
Stem Cell Based Treatment for Spinal Muscular Atrophy Receives Orphan Drug Designation
Regenerative Medicine FDA
 HSMN NewsFeed - 29 Feb 2008
California Stem Cell, Inc. Concludes Series A Financing
Regenerative Medicine Venture Capital
 HSMN NewsFeed - 20 Aug 2007
FDA Grants Tikvah Therapeutics, Inc. Orphan Drug Status for Sodium Phenylbutyrate for the Treatment of Spinal Muscular Atrophy
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
spinal muscular atrophy
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.